Call for Australian health-tech startups for world-best accelerator


The Texas Medical Centre Accelerator (TMCx) Medical Device 2018 cohort is now open for applications until the end of this week, as it works to accelerate medical device and digital health solutions in the world's largest medical centre.

Located in the TMC Innovation Institute, the TMCx accelerator is a four-month program providing startup companies with shared workspace, a curriculum tailored to the needs of health care entrepreneurs and the guidance of over 120 advisors from the front lines of the industry. Companies have access to the world’s most prominent medical centre, all without membership fees or equity sharing.

Participants further develop their companies by attending a variety of workshops and hands-on events to gain insights from experts in every facet of running a health-related business: clinical trials, FDA regulations, HIPAA/HITECH compliance, hospital procurement, commercial pilots, intellectual property, licensing, fundraising, marketing and other critical areas.

In addition, participants work with the TMCx team to refine strategies and build relationships across the Texas Medical Center. Companies network with key thought leaders and mentors during the Advisor Pitch Event, the TMC Expert Forum and other scheduled sessions. The four-month program culminates with TMCx Demo Day, an exclusive presentation to hundreds of investors, corporate partners, hospital stakeholders, media and other guests.

The TMCx team’s goal is to quickly and effectively connect entrepreneurs to stakeholders.

TMC is the largest medical centre in the world, with an extensive campus of 21 hospitals, 50 non-profit organisations and eight academic and research institutions, and thus has the capacity to provide unparalleled support for Australian health tech startups.

TMCx guides two cohorts of companies per year – one focused on Digital Health and the other on Medical Devices.

Recent participant of TMCx Stuart Ward, CEO of Ward MM – a Melbourne-based clinical pharmacist group – said of his experience:

“We have been able to establish ourselves in America in next to nothing, in terms of funding – and being involved in that health community network enabled us to expand really quickly as a result.”

Acceptance into the program involves a competitive process where Australian companies will be assessed against other Australian firms.

Applications for the 2018 TMCx Accelerator Medical Device 2018 cohort closes this Friday 11 May. More information is available online.